Last reviewed · How we verify
NCT03381131
Chinese Version of Fibromyalgia Criteria and Severity Scales Study
trial in Chinese Version in 327 participants. Completed in 30 December 2021.
30 December 2021
Quick facts
| Lead sponsor | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 327 |
| Start date | 1 October 2018 |
| Primary completion | 30 December 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across China |
Conditions studied
- Chinese Version — all drugs for Chinese Version →
- Fibromyalgia — all drugs for Fibromyalgia →
- Diagnosis — all drugs for Diagnosis →
- Fibromyalgia Impact Questionnaire — all drugs for Fibromyalgia Impact Questionnaire →
Sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Who can join
Adults 18 to 90, any sex, with Chinese Version or Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Up to now, there is no Chinese version of fibromyalgia diagnosis criteria and severity assessment scales. The aim of this study is to translate, adapt, and validate the Chinese version of the 2011 modification of the 2010 ACR preliminary criteria for the diagnosis of fibromyalgia (2011ModCr) and 2016 ACR revisions to the 2010/2011 fibromyalgia diagnostic criteria, as well as the Fibromyalgia Impact Questionnaire (FIQ-C).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Demographic Characteristics and Clinical Features of Fibromyalgia in China: A Cross-Sectional Study.
Jiao J, Cheng Z, Wang W, Zhao Y, et al · · 2021 · cited 12× · PMID 33813715 · DOI 10.1007/s40744-021-00303-1 -
A Chinese version of the revised Fibromyalgia Impact Questionnaire: A validation study.
Li YT, Jiang Q, Jia Y, Zhang YF, et al · · 2023 · cited 7× · PMID 36261882 · DOI 10.1111/1756-185x.14472 -
Validation of the 2011 and 2016 American college of rheumatology diagnostic criteria for fibromyalgia in a Chinese population.
Jiao J, Cheng ZY, Xiao YY, Wang H, et al · · 2023 · cited 6× · PMID 37634058 · DOI 10.1080/07853890.2023.2249921
Verify or expand the search:
- PubMed search for NCT03381131
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Guang'anmen Hospital of China Academy of Chinese Medical Sciences trials
Trials by the same sponsor.
- NCT07324148 — Acupuncture for Erectile Dysfunction · NA · not yet recruiting
- NCT07183813 — Acupuncture for Anxiety/Depression in Patients With Breast Cancer · NA · not yet recruiting
- NCT07150234 — Effectiveness of Acupuncture for Cervical Spondylotic Radiculopathy · NA · not yet recruiting
- NCT06996210 — Effect of Acupuncture on Chronic Nonspecific Neck Pain and Insomnia · NA · not yet recruiting
- NCT07079072 — Acupuncture for Lung Cancer-Related Fatigue · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03381131 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Last refreshed: 25 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03381131.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing